By the end of March, Pfizer and Moderna expect to have provided the U.S. government with a total of 220 million vaccine doses, up from the roughly 75 million shipped so far.
Lilly shares surge after its potential Alzheimer’s drug slows cognitive decline
The experimental drug, donanemab, could be a huge breakthrough for Lilly, which has spent billions of dollars over 30 years researching treatments for Alzheimer’s disease, only to see them fall short in clinical trials.Read More
Lilly acquiring gene therapy startup for up to $1 billion
Eli Lilly and Co. on Tuesday announced that it is buying New York-based Prevail Therapeutics Inc., an emerging player in the sizzling-hot area of gene therapies, which targets Parkinson’s disease and other brain-related maladies.Read More
Scaling up production of formerly niche substances such as lipid nanoparticles for a global vaccine drive has been among the most complex challenges behind the effort.
If you follow the daily drumbeat of news emanating out of Lilly Corporate Center, you might not grasp how phenomenally well the company is poised to perform in the coming years.
J&J’s vaccine was safe and offered strong protection against moderate to severe COVID-19, according to preliminary results from a massive international study.
The global business consulting firm McKinsey & Company has agreed to a $573 million settlement with 49 states over its role in advising companies on how to “supercharge” opioid sales amid an overdose crisis.
So far this month, drugmakers have hiked prices on 636 drugs, according to research by GoodRx, which tracks prescription drug prices and offer a mobile app to help consumers find the lowest prices on hundreds of drugs.
INCog BioPharma Services has purchased 16 acres of undeveloped land in Fishers for its planned new biopharmaceutical manufacturing facility. The $60 million project has grown in size.
The Sinopharm vaccine, like the AstraZeneca one, could be easier for countries around the world to handle since they can be stored at normal fridge temperatures.
The candidate made by Novavax Inc. is the fifth to reach final-stage testing in the U.S. Some 30,000 volunteers are needed to prove if the vaccine–a different kind than its Pfizer and Moderna competitors–really works and is safe.
Under the nearly $2 billion deal announced Wednesday, the companies will deliver at least 70 million additional doses by June 30, with the remaining 30 million to be delivered no later than July 31.
The lawsuit, filed Tuesday by the Justice Department, says the nation’s largest retailer did not properly screen prescriptions at its 5,000 pharmacies. The agency is seeking civil penalties that could total billions of dollars.
Red tape, staff shortages, testing delays and strong skepticism are keeping many patients and doctors from the drugs made by Eli Lilly and Co. and Regeneron Pharmaceuticals.
The Food and Drug Administration was evaluating a shot developed by Moderna Inc. and the National Institutes of Health and was expected to give it the green light soon, clearing the way for its use to begin as early as Monday.
Once FDA’s emergency use authorization is granted, Moderna will begin shipping millions of doses, earmarked for health workers and nursing home residents, to boost the largest vaccination effort in U.S. history.
The Food and Drug Administration said Wednesday that pharmacists can draw additional doses from vials of the Pfizer coronavirus vaccine, potentially expanding the country’s supply by millions of doses.
The vaccine appears poised for regulatory clearance after a detailed data review by Food and Drug Administration scientists confirmed the two-shot regimen was “highly effective” in a clinical trial and carried no serious safety concerns.
Lilly stock climbed Tuesday after the drugmaker laid out a better-than-expected revenue forecast and plans to buy a young company developing a potential Parkinson’s disease treatment.
Federal officials hope to have given both of the required vaccine doses to 100 million people by the end of March. It could take two to three more months to immunize enough people to prompt herd immunity.
The state of Indiana is set to receive more than 55,000 doses of the COVID-19 vaccine for health care workers next week, with the initial doses going to five pilot hospitals. By the end of next week, additional doses are expected at a total of 50 hospitals throughout the state.
The U.S. gave the final go-ahead Friday to the nation’s first COVID-19 vaccine, marking what could be the beginning of the end of an outbreak that has killed nearly 300,000 Americans.